Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant. This evidence concerns the gene SP1 and chronic myelogenous leukemia, BCR-ABL1 positive.